Custom lipid nanoparticle design for efficient, stable, and application-driven antigen delivery.
Lipid nanoparticles (LNPs) have become a highly versatile delivery platform for antigen-focused drug discovery, vaccine research, and immunology-oriented formulation development. By protecting fragile antigen cargos, improving cellular uptake, and enabling tunable immune presentation, LNP systems help researchers translate antigen concepts into experimentally testable delivery formats. However, antigen delivery is rarely a one-parameter formulation task. The molecular format of the antigen, lipid composition, particle size, surface chemistry, endosomal release behavior, and cargo accessibility must be optimized together to achieve reliable biological performance. BOC Sciences provides specialized lipid nanoparticle development services for antigen delivery, supporting mRNA-encoded antigens, protein antigens, peptide antigens, and multicomponent antigen systems through formulation design, encapsulation optimization, characterization, and functional evaluation.
Lipid nanoparticle structure for antigen deliveryWe support antigen delivery projects from early formulation screening to mechanism-oriented optimization. Our services are designed for pharmaceutical researchers, biotechnology teams, immunology groups, and project managers seeking a reliable LNP platform for antigen stabilization, intracellular delivery, antigen presentation, and immune-response-oriented formulation comparison.
For projects using mRNA as the antigen-encoding cargo, BOC Sciences develops ionizable lipid-based LNP systems that protect RNA, support cellular uptake, and facilitate cytosolic release for antigen expression.
Protein antigens often require careful handling to preserve conformational epitopes while improving delivery to antigen-presenting cells. Our LNP-based protein delivery services focus on maintaining antigen integrity while improving nanoparticle association and cellular access.
Short peptide antigens may show rapid diffusion, poor cellular uptake, or weak intracellular access when used without a carrier. Our LNP-based peptide delivery development supports hydrophilic, hydrophobic, amphiphilic, and modified peptide antigens.
Many antigen delivery projects require the co-delivery of antigen and immune-modulating molecules or the presentation of multiple antigen formats in one system. BOC Sciences supports rational LNP design for multicomponent formulations while controlling particle uniformity and cargo distribution.
For programs requiring improved interaction with selected immune cells or tissues, we provide targeted LNP development strategies based on lipid composition tuning and surface functionalization.
Antigen delivery performance depends strongly on whether the cargo is efficiently incorporated and remains associated with the LNP during storage and biological testing. Our LNP encapsulation efficiency optimization service helps identify formulation conditions that improve loading without compromising antigen quality.
Effective antigen delivery requires the integration of lipid chemistry, antigen biophysics, nanoparticle assembly, and immune-relevant performance evaluation. BOC Sciences applies a design-of-experiments mindset to compare formulation variables systematically rather than relying on a single generic LNP recipe.
Share your antigen format, target application, and preferred evaluation model. BOC Sciences can help design a formulation strategy that connects nanoparticle properties with antigen delivery performance.
Antigen delivery projects differ substantially in cargo structure, stability, uptake pathway, and desired presentation mechanism. BOC Sciences customizes LNP formulation and evaluation workflows based on antigen type, physicochemical properties, and the intended experimental readout.
| Antigen Cargo Type | Formulation Focus and Research Applications |
|---|---|
| mRNA-Encoded Antigens | Development of LNPs for antigen-encoding mRNA, including encapsulation optimization, particle size control, RNA protection, and expression-oriented formulation comparison. |
| Self-Amplifying RNA Antigens | Formulation design for larger RNA constructs requiring enhanced cargo protection, controlled particle assembly, and careful evaluation of RNA integrity after LNP preparation. |
| Protein Subunit Antigens | LNP systems designed to improve protein antigen association, reduce aggregation risk, and support delivery to antigen-processing cell models. |
| Peptide and Neoantigen Pools | Lipid-based encapsulation or association strategies for short antigenic peptides, long peptides, amphiphilic peptides, and multi-epitope mixtures. |
| Protein-RNA Combination Antigens | Co-delivery development for projects combining expressed antigen, surface antigen, or protein antigen with RNA cargo in one lipid nanoparticle system. |
| Surface-Displayed Antigens | Formulation approaches that present antigen on or near the LNP surface to support receptor interaction, antigen recognition, or multivalent display studies. |
| Adjuvant-Associated Antigen Systems | Co-formulation strategies for antigen plus immune-modulating molecules, with attention to compatibility, release behavior, and cargo distribution. |
| Fluorescent or Labeled Antigens | LNP development for tracking antigen uptake, intracellular localization, and antigen retention in cell-based or in vivo research models. |
Antigen-loaded LNPs often fail because formulation performance is judged only by particle size or encapsulation efficiency. BOC Sciences helps identify and resolve the deeper formulation issues that affect antigen delivery outcomes.
✔ Low Antigen Encapsulation
Charged, bulky, or conformationally sensitive antigens may not efficiently enter the lipid matrix. We screen lipid composition, buffer pH, ionic strength, and mixing conditions to improve antigen association.
✔ Antigen Aggregation or Denaturation
Protein antigens may lose activity or epitope accessibility during formulation. We apply mild preparation conditions, stabilizing excipients, and analytical checks to reduce structure-related failure.
✔ Poor Cellular Uptake
LNPs with unsuitable particle size, PEG-lipid density, or surface charge may show weak interaction with target cell models. We optimize physicochemical properties to improve uptake behavior.
✔ Inefficient Endosomal Release
Strong uptake does not always translate into antigen expression or presentation. We compare ionizable lipids and helper lipid ratios to improve intracellular cargo release.
✔ Instability During Storage or Testing
Antigen leakage, particle growth, and cargo degradation can distort performance data. We monitor size, PDI, zeta potential, and antigen retention across selected storage or assay conditions.
✔ Unclear Delivery Mechanism
When antigen response is weak, the limiting factor may be loading, uptake, intracellular release, or antigen expression. We combine characterization and functional assays to locate the bottleneck.
We review antigen type, molecular weight, charge profile, solubility, sequence or structural sensitivity, desired delivery model, and available analytical readouts to define the formulation strategy.
Multiple lipid ratios and preparation conditions are compared using microfluidic or controlled mixing workflows. Our microfluidic LNP production services support reproducible formulation screening for antigen-loaded nanoparticles.
Candidate formulations are evaluated using lipid nanoparticle characterization methods such as particle size, PDI, zeta potential, morphology, encapsulation efficiency, antigen retention, and structural integrity assessment.
Depending on the project goal, we evaluate uptake, intracellular localization, antigen expression, antigen release, or immune-cell-relevant response markers in in vitro or in vivo research models, then refine the formulation based on the data.
Challenge: A biotechnology research team developed an mRNA construct encoding a membrane-associated viral antigen. Initial LNP batches showed acceptable particle size around 95-120 nm and RNA encapsulation above 88%, but antigen expression in dendritic-cell-like models remained inconsistent.
Diagnosis: BOC Sciences compared eight formulations with different ionizable lipid ratios, cholesterol levels, and PEG-lipid contents. Uptake analysis showed that several formulations entered cells efficiently, but endosomal release was limited. The strongest uptake formulation was not the strongest expression formulation, indicating that intracellular release, rather than entry, was the primary bottleneck.
Solution: We adjusted the ionizable lipid/helper lipid balance and reduced PEG-lipid density within a controlled range to improve membrane interaction after uptake. We also screened citrate and acetate buffer conditions during nanoparticle assembly to preserve RNA integrity while improving particle uniformity. Candidate formulations were ranked by particle size, PDI, RNA retention, uptake signal, and antigen expression intensity.
Result: The optimized formulation maintained a particle size below 110 nm, reduced PDI from 0.21 to 0.12, and increased antigen expression signal approximately 3.4-fold compared with the starting formulation. The client received a formulation decision matrix identifying two lead compositions suitable for further biological comparison.
Challenge: A research group needed to deliver a recombinant protein antigen containing conformational epitopes. Direct mixing with cationic lipid systems produced visible aggregation, broad particle distributions above 250 nm, and reduced antigen recognition in a binding assay.
Diagnosis: Our team found that strong electrostatic interaction between the protein and positively charged lipid surface caused partial aggregation and epitope masking. A standard high-charge formulation improved association but compromised antigen accessibility.
Solution: BOC Sciences evaluated three loading strategies: internal encapsulation during controlled mixing, post-insertion surface association, and mild lipid-interface adsorption under low-salt buffer conditions. We monitored particle size, antigen recovery, free protein fraction, and binding signal after formulation. The mild lipid-interface adsorption strategy produced the best balance between association and epitope accessibility.
Result: The selected formulation achieved a mean particle size of 135 nm with PDI below 0.16, retained more than 80% antigen binding signal relative to the unformulated protein control, and reduced visible aggregation during short-term storage testing. The project team used these data to select the surface-associated LNP format for further cell-based evaluation.
Cargo-Specific Formulation LogicWe do not apply the same LNP formula to every antigen. RNA, protein, peptide, and multicomponent antigens are formulated according to their molecular structure, charge, stability, and delivery mechanism.
Integrated LNP PlatformBOC Sciences combines lipid nanoparticle formulation, controlled production, analytical characterization, and performance evaluation within one coordinated development workflow.
Mechanism-Oriented OptimizationWe evaluate loading, uptake, intracellular release, expression, and antigen retention to identify the true limiting factor behind poor delivery performance.
Flexible Production MethodsOur LNP process optimization capabilities help refine flow conditions, lipid concentration, buffer composition, and post-processing parameters for consistent antigen-loaded LNP preparation.
Broad Antigen ExperienceWe support antigen delivery projects involving mRNA, protein subunits, peptides, neoantigen pools, labeled antigens, and co-delivery systems for immunology-focused discovery research.
Lipid nanoparticles are valuable antigen delivery systems because they can protect fragile antigenic payloads, improve dispersion in biological media, and support efficient interaction with immune-relevant cells. For protein, peptide, or nucleic acid antigens, LNPs can reduce exposure to enzymatic degradation and help maintain payload integrity during formulation handling. Their lipid composition can also be adjusted to influence particle size, surface charge, antigen association, and release behavior. For research teams developing vaccine-related or immunology-focused delivery platforms, LNPs offer a flexible formulation route that can be adapted to different antigen structures, including soluble proteins, membrane-associated antigens, mRNA-encoded antigens, and antigen-adjuvant combinations.
LNPs can be designed for several antigen formats, but the optimal formulation strategy depends strongly on the antigen type. Nucleic acid antigens such as mRNA or self-amplifying RNA are commonly complexed through ionizable lipid systems, while peptide and protein antigens may require encapsulation, surface association, or lipid conjugation approaches. Some hydrophobic or membrane-derived antigens may benefit from lipid-phase incorporation, whereas highly soluble proteins often need careful buffer, charge, and lipid ratio optimization to avoid aggregation or low loading efficiency. BOC Sciences can help evaluate antigen physicochemical properties and develop formulation strategies that balance encapsulation, particle stability, antigen preservation, and downstream immunological research needs.
Antigen loading efficiency is usually evaluated by distinguishing free antigen from LNP-associated antigen and then quantifying the amount retained within or on the nanoparticle system. The analytical method depends on the antigen format. Protein and peptide antigens may be assessed using HPLC, fluorescence labeling, UV-based assays, or immunoassay-compatible readouts, while nucleic acid antigens are often quantified using dye-binding assays, electrophoretic analysis, or chromatography-based methods. A reliable evaluation should also consider whether the separation method disrupts the LNP structure or causes antigen loss. BOC Sciences develops antigen-specific analytical workflows to measure loading efficiency, payload retention, and formulation consistency across screening batches.
Several formulation variables can strongly influence LNP antigen delivery performance, including ionizable lipid structure, helper lipid ratio, cholesterol content, PEG-lipid level, particle size distribution, antigen-to-lipid ratio, buffer composition, and mixing conditions. For protein and peptide antigens, conformational stability and surface exposure are also critical because structural changes may reduce antigen recognition in downstream assays. For nucleic acid antigens, encapsulation efficiency, RNA integrity, and endosomal release potential are key considerations. During formulation development, it is important to screen multiple lipid compositions and preparation parameters rather than relying on a single prototype. This helps identify a formulation that meets both physicochemical and functional research requirements.
Yes, LNPs can be engineered to co-deliver antigens and immunostimulatory components when the formulation is carefully designed around compatibility, localization, and release behavior. Co-delivery may help place antigenic material and immune-activating signals within the same particulate system, which can be useful for immunology and vaccine research models. However, combining multiple payloads can introduce challenges such as reduced loading efficiency, particle instability, premature leakage, or interference between the antigen and adjuvant. BOC Sciences supports formulation screening for antigen-adjuvant LNP systems by optimizing lipid composition, payload ratio, preparation process, and characterization methods to identify stable candidates with suitable particle attributes and antigen retention profiles.
